These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23743161)

  • 21. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
    Yan M; Wen Y; Yang L; Wu X; Lu X; Zhang B; Huang W; Li P
    Trials; 2016 May; 17(1):259. PubMed ID: 27216240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
    Lian F; Tian J; Chen X; Li Z; Piao C; Guo J; Ma L; Zhao L; Xia C; Wang CZ; Yuan CS; Tong X
    PLoS One; 2015; 10(6):e0130550. PubMed ID: 26098833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise-induced albuminuria increases over time in individuals with impaired glucose metabolism.
    Brzezinski RY; Friedensohn L; Shapira I; Zeltser D; Rogowski O; Berliner S; Grupper A; Shenhar-Tsarfaty S
    Cardiovasc Diabetol; 2020 Jun; 19(1):90. PubMed ID: 32539802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
    Jin D; Huang WJ; Meng X; Yang F; Bao Q; Zhang MZ; Yang YN; Ni Q; Lian FM; Tong XL
    Trials; 2019 Dec; 20(1):756. PubMed ID: 31864393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Greater impairment of postprandial triacylglycerol than glucose response in metabolic syndrome subjects with fasting hyperglycaemia.
    Jackson KG; Walden CM; Murray P; Smith AM; Minihane AM; Lovegrove JA; Williams CM
    Metabolism; 2013 Aug; 62(8):1065-9. PubMed ID: 23598085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.
    Feig PU; Shah S; Hermanowski-Vosatka A; Plotkin D; Springer MS; Donahue S; Thach C; Klein EJ; Lai E; Kaufman KD
    Diabetes Obes Metab; 2011 Jun; 13(6):498-504. PubMed ID: 21272190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
    Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
    Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Waist circumference provides an indication of numerous cardiometabolic risk factors in adults with cerebral palsy.
    Ryan JM; Crowley VE; Hensey O; McGahey A; Gormley J
    Arch Phys Med Rehabil; 2014 Aug; 95(8):1540-6. PubMed ID: 24742941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of the metabolic syndrome profile by soluble fibre - guar gum - in patients with type 2 diabetes: a randomised clinical trial.
    Dall'Alba V; Silva FM; Antonio JP; Steemburgo T; Royer CP; Almeida JC; Gross JL; Azevedo MJ
    Br J Nutr; 2013 Nov; 110(9):1601-10. PubMed ID: 23551992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
    Yang X; Zhang B; Lu X; Yan M; Wen Y; Zhao T; Li P
    BMC Complement Altern Med; 2016 Jul; 16():246. PubMed ID: 27460780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of Chinese herbal medicine Shen-Qi Hua-Yu formula in patients with diabetic lower extremity artery disease: Study protocol of a multi-center, randomized, double-blind, placebo-controlled trial.
    Leng Y; Gao H; Fu X; Xie H; Hu Z; Zhu J; Liu X; Zhou X; Xie Z; Xie C
    Medicine (Baltimore); 2020 Jan; 99(3):e18713. PubMed ID: 32011447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of microalbuminuria and high-normal 24-hour urinary albumin excretion with metabolic syndrome and its components in the general Chinese population: cross-sectional study.
    Xu J; Ma J; Chen X; Yan L; Cai X; Guo X; Zhang Y; Wu J
    BMJ Open; 2019 Nov; 9(11):e031443. PubMed ID: 31712338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial.
    Kjær TN; Ornstrup MJ; Poulsen MM; Stødkilde-Jørgensen H; Jessen N; Jørgensen JOL; Richelsen B; Pedersen SB
    J Clin Endocrinol Metab; 2017 May; 102(5):1642-1651. PubMed ID: 28182820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity of various body indices and visceral adiposity index in predicting metabolic syndrome among Chinese patients with adult growth hormone deficiency.
    Qing L; Wei R; Chan L; Xiaoya Z; Xin X
    J Endocrinol Invest; 2017 Jun; 40(6):653-661. PubMed ID: 28233232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial.
    Sangouni AA; Taghdir M; Mirahmadi J; Sepandi M; Parastouei K
    Nutr J; 2022 Oct; 21(1):62. PubMed ID: 36192751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic syndrome and gallstone disease.
    Chen LY; Qiao QH; Zhang SC; Chen YH; Chao GQ; Fang LZ
    World J Gastroenterol; 2012 Aug; 18(31):4215-20. PubMed ID: 22919256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized double-blind placebo-controlled study of Pu'er tea extract on the regulation of metabolic syndrome.
    Chu SL; Fu H; Yang JX; Liu GX; Dou P; Zhang L; Tu PF; Wang XM
    Chin J Integr Med; 2011 Jul; 17(7):492-8. PubMed ID: 21725873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.